Astellas Pharma Inc., Evec Team Up for Antibody Pact Worth Up to $176.8 Million

Published: Sep 06, 2011

Astellas is set to get worldwide manufacturing, development and commercialization rights for Evec's fully-human antibodies targeting infectious diseases. Evec is a developer of a range of human monoclonal antibodies in multiple therapeutic areas, including cancer, inflammatory diseases and infectious diseases. Astellas will pay a sum of JPY0.6bn as an upfront payment to Evec, under the license agreement.

Back to news